CD8A and hemophilia: In a prior study on IM F9 gene transfer in hemophilia B mice, we found that the CpG-depleted vector (using the same enhancer/promoter elements as here) substantially reduced but again did not eliminate CD8+ T-cell responses (using a similar AAV1 vector dose as the high dose in this study with the OVA transgene) [22].